Acquired bullous dermatoses belong to a group of skin and/or mucosa diseases. Clinical presentation with blisters or bullae are an outcome of autoantibodies directed against molecular components of desmosomes and basement membrane zone. These diseases are also called autoimmune bullous dermatoses because of the autoimmune background in the disease development. The classification of this heterogeneous disease group is based on the location of blister formation (separation), therefore it's classified as intraepidermal and subepidermal bullous dermatosis. Acquired bullous dermatoses are usually chronic and unpredictable in development, and some of them can be lethal, for example pemhigus vulgaris. Frequent controls are usually required, also in an interdisciplinary team and, in some cases, a life time therapy. In this thesis the most important acquired bullous dermatoses therapy principles are described. In acquired bullous dermatoses therapy should be applied as soon as possible, even if a patient presents with a mild clinical symptoms. Doctor's experience in treating this illness is crucial because strictly defined algorithm of therapy does not exist. Each patient should be approached individually and parameters for determining a type of therapy and doses should be also estimated.